Serum human epididymis protein 4 (HE4), a promising ovarian cancer biomarker [9], is less influenced by benign gynaecological disease, with evidence suggesting it is more specific than CA125 for ovarian cancer [10,11]. This evidence concerns the gene WFDC2 and ovarian carcinoma.